Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease

Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting an Astellas cancer drug for an eye disease that has attracted lots of VC and pharma attention in recent years. Sling Therapeutics ...